₹6.7
▲ +0.4 +6.35%
16 Jun 2026
BSE Listed · Pharmaceuticals
Vivimed Labs Ltd. (532660)
Volume: 2,155Avg Vol 1W: 16,264Avg Vol 1M: 15,03952W Range:₹4.95₹29.4
Key Ratios
Updated just nowMarket Cap₹52 Cr
Current Price₹6.7
Previous Close₹6.3
High / Low (52w)₹29.4 / ₹4.95
Volume2,155
Avg Vol (1W)16,264
Avg Vol (1M)15,039
Stock P/E—
Book Value₹-5.79
Dividend Yield0%
ROE50.81%
ROA-3.78%
Revenue (TTM)—
Revenue Growth-22%
Profit Margin-41.79%
Total Debt₹64 Cr
Shares Outstanding8 Cr
Face Value₹2
EPS (TTM)₹-2
P/B0
Debt / Equity-8.01
50 DMA₹6.6
200 DMA—
Day change+6.35%
Price Chart
₹6.3▼ 76.24% · 1Y
2025-12-182026-06-16
20-day avg volume: 16K shares
Pros
- Healthy return on equity of 50.8%.
- Company is almost debt-free.
Cons
- Revenue fell 24% YoY.
- Company is loss-making at the latest annual result.
- Negative book value per share.
Quarterly Results
| Metric | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sept 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sept 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sept 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sept 2020 | Jun 2020 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹16 Cr | ₹21 Cr | ₹21 Cr | ₹26 Cr | ₹37 Cr | ₹25 Cr | ₹29 Cr | ₹39 Cr | ₹41 Cr | ₹34 Cr | ₹35 Cr | ₹37 Cr | ₹56 Cr | ₹44 Cr | ₹50 Cr | ₹61 Cr | ₹57 Cr | ₹54 Cr | ₹65 Cr | ₹39 Cr | ₹278 Cr | ₹222 Cr | ₹323 Cr | ₹236 Cr |
| EBITDA | ₹-16 Cr | ₹-6 Cr | ₹-5 Cr | ₹-4 Cr | ₹-5 Cr | ₹-5 Cr | ₹-15 Cr | ₹-27 Cr | ₹-3 Cr | ₹-8 Cr | ₹-5 Cr | ₹-260 Cr | ₹-9 Cr | ₹-13 Cr | ₹-13 Cr | ₹-5 Cr | ₹-12 Cr | ₹-15 Cr | ₹7 Cr | ₹-19 Cr | ₹-34 Cr | ₹0 Cr | ₹31 Cr | ₹-36 Cr |
| Net Profit | ₹-17 Cr | ₹-7 Cr | ₹-5 Cr | ₹-6 Cr | ₹-6 Cr | ₹-5 Cr | ₹-15 Cr | ₹5 Cr | ₹-16 Cr | ₹-20 Cr | ₹-16 Cr | ₹-266 Cr | ₹-18 Cr | ₹-22 Cr | ₹-22 Cr | ₹-18 Cr | ₹-24 Cr | ₹-23 Cr | ₹-2 Cr | ₹-27 Cr | ₹-50 Cr | ₹-14 Cr | ₹13 Cr | ₹-61 Cr |
| EPS | -1.94 | -0.85 | -0.64 | -0.68 | -0.7 | -0.6 | -1.78 | 0.62 | -1.88 | -2.38 | -1.82 | -31.14 | -2.1 | -2.58 | -2.6 | -2.15 | -2.77 | -2.73 | -0.27 | -3.22 | -5.8 | -1.59 | 1.5 | -7.12 |
Profit & Loss (Annual)
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| Revenue | ₹121 Cr | ₹159 Cr | ₹188 Cr | ₹239 Cr | ₹871 Cr | ₹1,067 Cr |
| EBITDA | ₹-29 Cr | ₹-43 Cr | ₹-295 Cr | ₹-25 Cr | ₹-16 Cr | ₹-51 Cr |
| Net Profit | ₹-32 Cr | ₹-45 Cr | ₹-329 Cr | ₹-68 Cr | ₹-72 Cr | ₹-109 Cr |
| EPS | -3.74 | -5.32 | -38.46 | -7.92 | -8.42 | -12.77 |
Balance Sheet
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| Total Assets | ₹921 Cr | ₹951 Cr | ₹995 Cr | ₹1,266 Cr | ₹1,289 Cr | ₹2,210 Cr |
| Total Liabilities | ₹956 Cr | ₹956 Cr | ₹956 Cr | ₹902 Cr | ₹858 Cr | ₹1,375 Cr |
| Equity | ₹-35 Cr | ₹-5 Cr | ₹39 Cr | ₹364 Cr | ₹432 Cr | ₹835 Cr |
| Total Debt | ₹64 Cr | ₹64 Cr | ₹62 Cr | ₹61 Cr | ₹58 Cr | ₹470 Cr |
Cash Flow
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| Operating | ₹-2 Cr | ₹-24 Cr | ₹35 Cr | ₹28 Cr | ₹542 Cr | ₹99 Cr |
| Investing | ₹-5 Cr | ₹28 Cr | ₹-5 Cr | ₹-16 Cr | ₹404 Cr | ₹-196 Cr |
| Financing | ₹5 Cr | ₹-6 Cr | ₹-34 Cr | ₹-10 Cr | ₹-1,015 Cr | ₹72 Cr |
| Free Cash Flow | ₹-2 Cr | ₹-24 Cr | ₹35 Cr | ₹28 Cr | ₹542 Cr | ₹100 Cr |
Shareholding
Promoter 7.57% Institutions 1.64% Public 90.67%
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search